Mild to Moderate Alzheimer Dementia with Insufficient Neuropathological Changes

Recently, ∼16% of participants in an anti-Aβ passive immunotherapy trial for mild-to-moderate Alzheimer disease (AD) had a negative baseline amyloid positron emission tomography (PET) scan. Whether they have AD or are AD clinical phenocopies remains unknown. We examined the 2005-2013 National Alzhei...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Serrano-Pozo, Alberto, Qian, Jing, Monsell, Sarah E., Blacker, Deborah, Gómez-lsla, Teresa, Betensky, Rebecca A., Growdon, John H., Johnson, Keith, Frosch, Matthew P., Sperling, Reisa A., Hyman, Bradley T.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4016558/
https://ncbi.nlm.nih.gov/pubmed/24585367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ana.24125
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak